McKesson Corporation (MCK)

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? McKesson (MCK), which belongs to the

To see how that earnings based view stacks up against a full cash flow model, it is worth looking at how the SWS DCF model treats McKesson’s future cash generation and discount rate assumptions, and where that leaves the estimated value per share relative to today’s $768 price. See what the numbers …

The stock of prescription drug distributor has risen by 2.84% in the past month, lagging the Medical sector's gain of 7.96% and overreaching the S&P 500's loss of 2.9%. Market participants will be closely following the financial results of McKesson in its upcoming release. The company plans to annou…

McKesson stock has faced downward pressure in recent weeks due to concerns over GLP-1 (glucagon-like peptide-1) drug pricing impacts on distribution margins. Strong Q3 fiscal 2026 results prompted raised full-year adjusted EPS (earnings per share) guidance to $38.80-$39.20.

Micron surges 3.28% today to $1014.11 after strong Q3 results and AI chip demand, overcoming short-term resistance levels.